Literature DB >> 8561032

Patient attitudes to myelography, computed tomography and magnetic resonance imaging when examined for suspected lumbar disc herniation.

M J Albeck1, B Danneskiold-Samsøe.   

Abstract

In reports of diagnostic methods in disorders of the spine focus is centred on diagnostic resolution, while psychological effects and patients' discomfort are often disregarded. To get a comprehensive picture of the appropriateness of a new technology the latter factors need to be explored and included in an assessment. In a prospective study, eight patients with signs of lumbar disc herniation underwent myelography, computed tomography and magnetic resonance imaging. A structured patient interview on attitudes to these technologies was carried out after all three examinations had been carried out. Myelography was most often reported painful and unpleasant among the three modalities. Discomfort due to magnetic resonance imaging stem from the narrow calibre of the machine and the noise. In computed tomography immobilization was the main reason for discomfort. Altogether most patients preferred computed tomography. In view of the fact that myelography must be considered as diagnostically inferior to the other two examinations, the reported discomfort from myelography indicates that computed tomography and magnetic resonance imaging should be the primary examinations for patients with lumbar disc herniation.

Entities:  

Mesh:

Year:  1995        PMID: 8561032     DOI: 10.1007/bf01404939

Source DB:  PubMed          Journal:  Acta Neurochir (Wien)        ISSN: 0001-6268            Impact factor:   2.216


  15 in total

1.  Lumbar radiculography with metrizamide. A nonionic water-soluble contrast medium.

Authors:  I O Skalpe; P Amundsen
Journal:  Radiology       Date:  1975-04       Impact factor: 11.105

2.  Patients' attitudes toward informed consent for intravenous contrast media.

Authors:  K D Hopper; P S Houts; M A McCauslin; Y L Matthews; R J Sefczek
Journal:  Invest Radiol       Date:  1992-05       Impact factor: 6.016

3.  Which factors affect reported headache incidences after lumbar myelography? A statistical analysis of publications in the literature.

Authors:  T Sand
Journal:  Neuroradiology       Date:  1989       Impact factor: 2.804

4.  The neuroradiographic diagnosis of lumbar herniated nucleus pulposus: II. A comparison of computed tomography (CT), myelography, CT-myelography, and magnetic resonance imaging.

Authors:  R P Jackson; J E Cain; R R Jacobs; B R Cooper; G E McManus
Journal:  Spine (Phila Pa 1976)       Date:  1989-12       Impact factor: 3.468

5.  Lumbar herniated disk disease and canal stenosis: prospective evaluation by surface coil MR, CT, and myelography.

Authors:  M T Modic; T Masaryk; F Boumphrey; M Goormastic; G Bell
Journal:  AJR Am J Roentgenol       Date:  1986-10       Impact factor: 3.959

6.  A controlled comparison of myelography, computed tomography, and magnetic resonance imaging in clinically suspected lumbar disc herniation.

Authors:  M J Albeck; J Hilden; L Kjaer; S Holtås; J Praestholm; O Henriksen; F Gjerris
Journal:  Spine (Phila Pa 1976)       Date:  1995-02-15       Impact factor: 3.468

7.  The indications for metrizamide myelography. Relationship with complications after myelography.

Authors:  H N Herkowitz; R L Romeyn; R H Rothman
Journal:  J Bone Joint Surg Am       Date:  1983-10       Impact factor: 5.284

8.  Potential complications in myelography: I. Technical considerations.

Authors:  R S Seigel; A G Williams; R E Waterman
Journal:  AJR Am J Roentgenol       Date:  1982-04       Impact factor: 3.959

9.  Neuropsychologic reactions and other side effects after metrizamide myelography.

Authors:  O Hauge; H Falkenberg
Journal:  AJR Am J Roentgenol       Date:  1982-08       Impact factor: 3.959

10.  Barium meal or endoscopy? A prospective randomized study of patient preference and physician decision making.

Authors:  G W Stevenson; G Norman; R Frost; S Somers
Journal:  Clin Radiol       Date:  1991-11       Impact factor: 2.350

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.